Free Patent/Trademark Report to Commissioner - District Court of Delaware - Delaware

Case 1 :07-cv-00138-JJF Document 66 Filed 06/24/2008 Page 1 of 1
% AO 120 Rev. 3/O4
TO_ Mail Stop 8 REPORT ON THE
` Director of the U.S. Patent and Trademark Office FILING OR DETERMINATION OF AN
P.O. Box 1450 ACTION REGARDING A PATENT OR
Alexandria, VA 22313-1450 TRADEMARK
In Compliance with 35 U.S.C. § 290 and/or I5 U.S.C. § ll I6 you are hereby advised that a court action has been
filed in the U.S. District Court Delaware on the following X Patents or El Trademarks:
DOCKET NO. DATE FILED U.S. DISTRICT COURT
07cvl38 3/9/2007 DISTRICT OF DELAWARE
PLAINTIFF DEFENDANT
Pfizer Inc., Pfizer Pharmaceuticals, LLC, Pfizer Limited C.P., Ranbaxy Laboratories Limited and Ranbaxy Inc.
Pharmaceuticals Intemational C.V., Pfizer Ireland Pharmaceuticals,
Warner-Lambert Company, Warner-Lambert Company LLC. and
Wamer-Lambert Expert LTD.
PATENT OR DATE OF PATENT
TRADEMARK NO OR TRADEMARK l—lOLDER OF PATENT OR TRADEMARK
I 4,681,893 7/2 I/1987 Warner-Lambert Company
2 6,455,574 Bl 9/24/2002 Pfizer Inc.
3
3
3
In the above—-entitled case. the following patent(s)/ trademarkts) have been included:
DATE INCLUDED INCLUDED BY
lj Amendment lj Answer E Cross Bill I] Other Pleading
PATENT OR DATE OF PATENT
TRADEMARK NO. OR TRADEMARK HOLDER OF PATENT OR TRADEMARK
3
3 __
3
3
In the above——entitled case, the following decision has been rendered orjudgement issued:
DECISION/JUDGEMENT
See Attached Consent Order and Stipulated injunction (re Patent No. 6,455,574)
CLERK (BY) DEPUTY CLERK DATE
PETER T. DALLEO, CLERK OF COURT . ° 6/24/2008
' I , ~ Mui LL
Copy l—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case tile copy

Case 1:07-cv-00138-JJF Document 66-2 Filed 06/24/2008 Paget of3
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
)
PFIZER INC., PFIZER )
PHARMACEUTICALS, LLC, PFIZER )
LIMITED, C.P. PHARMACEUTICALS )
INTERNATIONAL C.V., PFIZER IRELAND )
PHARMACEUTICALS, WARNER- )
LAMBERT COMPANY, )
WARNER-LAMBERT COMPANY LLC )
and WARNER-LAMBERT EXPORT LIMITED, )
)
Plaintiffs/Counterclaim-Defendants )
)
v. )
) C.A. N0. 07-cv-138-JJF
RANBAXY LABORATORIES LIMITED )
AND RANBAXY INC., )
)
Defendants/Counterclaim-Plaintiffs. )
)
CONSENT ORDER AND STIPULATED INJUNCTION
WHEREAS, plaintiffs/counterclaim defendants Pfizer Inc., Pf`1zer
Pharmaceuticals LLC, Pfizer Limited, C.P. Pharmaceuticals International C.V., Pfizer
Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company, LLC
and Warner-Lambert Export Limited ("Pfizer") own U.S. patents covering the
manufacture, sale and use of products containing atorvastatin and amlodipine and any
pharmaceutically acceptable salts thereof including without limitation U.S. patent
6,455,574 ("Caduet Patent");
WHEREAS, defendant/counterclaim plaintiff Ranbaxy Laboratories Limited and
Ranbaxy, Inc. ("Ranbaxy") has submitted to the U.S. Food and Drug Administration
Abbreviated New Drug Application No. 78-747 ("Ranbaxy ANDA") for approval to

Case 1:07-cv-00138-JJF Document 66-2 Filed 06/24/2008 Page 2 of 3
market and sell a generic product containing atorvastatin calcium and amlodipine
besylate;
WHEREAS, Pfizer and Ranbaxy are parties to litigation relating to the Ranbaxy
ANDA and Caduet Patents, and Ranbaxy desires to sell a generic product containing
atorvastatin calcium and amlodipine besylate under the Ranbaxy ANDA free from claims
of infringement by Pfizer under the Caduet Patent;
WHEREAS, Pfizer andR anbaxy have entered intoa Settlement andL icense
Agreement, dated as of June l7, 2008 ("Settlement Agreement"), pursuant to which the
parties have resolved this action and Pfizer has granted Ranbaxy certain rights to its
portfolio of patents relating to atorvastatin;
NOW THEREFORE, Pfizer and Ranbaxy stipulate that:
l. Ranbaxy, its officers, agents,s ervants, employees and attorneys, and those
persons in active concert or participation with Ranbaxy are enjoined until November 30,
20ll from engaging in the commercial manufacture, use, offer to sell, or sale within the
UnitedS tates, or importationi ntot he UnitedS tates, of any product comprising the
chemical compounds atorvastatin calcium and amlodipine besylate. This injunction shall
terminate automatically upon the U.S. Generic Lipitor Commencement Date as defined in
the Settlement Agreement.
2. The Protective Order entered by the Court in this action shall remain in
full force and effect notwithstanding this Consent Order and Stipulated Injunction.
3. All claims and counterclaims are dismissed with prejudice, and each Party
shall bear its own costs, expenses and attorneys’ fees in connection with this action.
4. The parties waive any right of appeal from this Order.
2

Case 1:07-cv-00138-JJF Document 66-2 Filed 06/24/2008 Page 3 of 3
5. The Court reserves jurisdiction over this Consent Order in the evento f any
dispute concerning it.
Dated: June 18,200 8 Dated: June 18, 2008
By: /s/ Rudolf E. Hutz By: /s/ Frederick L. Cottrell, 111
R¤d<>1fE· Hurz (#484) Frederick L.c ottrell, III (#2555)
·l€fI°F€Y B- BOW (#998) Email: cottrell@rl£com
Mary W· Bourke (#2356) Richards, Layton & Finger
CONNOLLY BOVE LODGE & HUT Z LLP gm Rodney Square
The Nemours Building p_O_ BOX 551
1007 North Orange Street Wilmington, DE 19g99
P-Q BOX 2207 (302) 658-6541
Wrlmrrrgtvrrr DE 198992207 Attorneys for Defendants
(302) 658-9141
Attorneys for the Plaint%r Ofcounsélz
Joseph M. Reisman
William R. Zimmerman
Payson LeMeilleur
KNOBBE, MARTENS, OLSON
& BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
(949) 760-0404
Attorneys for Defendants
IT IS SO ORDERED, this @jQ day of , 2008.
I
xi.; -{..A§ '
q onor le eph J. Earn r.
~ d States District Judge
3